Hyperoxaemia in patients undergoing mechanical ventilation (MV) has been found to be an independent predictor of worse outcome and in-hospital mortality in some conditions. Data suggests that a fraction of inspired oxygen (FiO 2 ) of 0.4 or lower may produce hyperoxaemia although it is commonly accepted without adjustment in ventilator settings. The primary aim of this study was to observe current practice at one Australian tertiary intensive care unit (ICU) with regard to prescription and titration of oxygen (O 2 ) in patients undergoing MV, in particular whether they received higher FiO 2 than required according to arterial blood gas (ABG) results, and whether there was FiO 2 titration as a response to initial ABG results during the 12 hours following. A retrospective observational study of 151 ICU patients undergoing MV between November 2013 and February 2014 was conducted, with ABGs as the primary outcome measure. There were 250 ABG measures, with mean FiO 2 0.38 (range 0.3-1.0) and mean PaO 2 114 mmHg (standard deviation 36). Over all observations, 197 (79%) were of FiO 2 ≤0.4, however no patients were ventilated on room air (FiO 2 0.21) and 114 (46%) were in the hyperoxaemic range. Oxygen titration (up or down) occurred in 31% of patients. Morning ABGs were taken at a time suggested by ICU guidelines, and on review of these measures, the mean FiO 2 was lower than that purported to create toxicity. Subsequently, almost one-third of the cohort had their FiO 2 titrated, however there was a floor effect whereby 39%-43% of the cohort received an FiO 2 of 0.3.
Introduction
A healthy group of people breathing room air (21% oxygen concentration) will have a normal pressure of arterial oxygen (PaO 2 ) of 80-110 mmHg and arterial oxygen saturation (SaO 2 ) of 95%-100% 1 . Historically the accepted recommendation was that critically ill patients should be administered high concentration oxygen (O 2 ) immediately, with target SaO 2 of 94%-98% for most acutely ill patients, or 88%-92% for those at risk of hypercapnic respiratory failure 2 . In light of relatively new data suggesting that hyperoxia is a common occurrence, an independent predictor of worse outcome in some conditions such as traumatic brain injury 3 and myocardial infarction 4 , and an independent predictor of mortality following cardiac arrest 5, 6 , there is currently a new consensus that the delivery of a high fraction of inspired oxygen (FiO 2 ) may be hazardous.
Hyperoxia of the lung is presumed to precipitate lung injury through the production of reactive oxygen intermediates 7, 8 , and oxygen toxicity during mechanical ventilation (MV) is presumed to occur at FiO 2 levels exceeding 0.4 9 . Correspondingly, a Canadian self-reported survey of intensivists indicated a consensus that levels of FiO 2 up to 0.4 are ideal when the PaO 2 permits 10 . Clinically, the reduction of FiO 2 to safe levels through the appropriate use of positive end-expiratory pressure and manipulation of mean airway pressure is a common and more appropriate goal 9 to improve oxygenation.
However, despite the suggestion in published guidelines for the use of emergency O 2 that delivery devices and flow rates should be titrated to keep the SaO 2 in the target range 2 , adjustments are often only made to FiO 2 within a certain range. Specifically, it has been demonstrated that hyperoxia is accepted without adjustment in ventilator settings if FiO 2 is 0.4 or lower 11 . Similarly, the medical prescription of oxygen has traditionally been more concerned with lower pulse oximetry (SpO 2 ) 'limits of action' rather than upper limits, and even when upper limits are prescribed, one study observed exceeding upper limits of prescription 59% of the time 12 .
The primary aim of this study was to observe current practice at one Australian tertiary hospital with regard to the prescription and titration of O 2 in mechanically ventilated intensive care unit (ICU) patients. In particular, whether patients: 1. Received a higher FiO 2 than they required according to corresponding mean PaO 2 in arterial blood gas (ABG) results, and 2. underwent titration of the delivery of the FiO 2 as a response to first ABG results during the 12 hours following.
Materials and methods

Design
This was an observational study of the normal clinical practice of providing O 2 for mechanically ventilated patients in the 23-bed level 3 ICU at the Sir Charles Gairdner Hospital (SCGH). The hospital quality improvement committee approved the study (reference number QI 4417).
Inclusion/exclusion criteria
All patients admitted to ICU who were undergoing invasive MV using an Evita XL ventilator (Dragermedical, Lubeck, Germany) for a minimum of six hours were considered for inclusion in the study. Patients without arterial lines who did not have ABGs sampled were excluded as were those undergoing extracorporeal membrane oxygenation.
Outcome measures
Outcome variables (as observed and recorded at the bedside) were ABGs and SpO 2 , including the time at which they were observed. Other demographic data were also collected in order to describe the cohort, including the patient age, gender, and Acute Physiology and Chronic Health Evaluation (APACHE) II diagnostic grouping and score.
Data collection process
Routine ICU protocol was that all mechanically ventilated patients had ABGs taken a minimum of twice daily (0600 and 1800 hours).
There is evidence to suggest that paramedical services and hospital emergency personnel routinely apply O 2 to patients with significant illness 13, 14 and there may be significant variation in the O 2 management of emergency department patients with such diseases as chronic obstructive pulmonary disease 15 . As ICU patients may be transported and/or admitted to ICU with higher oxygenation targets that are subsequently titrated down as required over the first few hours after admission, strict study guidelines were in place in order that data collected for use in the study reflected only ICU practice. As such, although other ABGs may have been taken and recorded, only Day 2 (of MV) data were considered for the study, and these data were only included a minimum of six hours since commencement of MV. Patients commencing MV before midnight had the first study ABG observed at around 0600 the following day (day two, with minimum time since commencement of MV being six hours); patients admitted after midnight had the first study ABG observed the following day at around 0600 (day two, with maximum time since commencement of MV being 30 hours). In this way the level of FiO 2 being delivered reflected the care of the ICU team rather than that of other specialties and patient transfer practices.
The next ABG to be measured more than four hours after the first sample and prior to extubation or death was recorded. These data were collected to demonstrate evidence of titration of FiO 2 as a response to the initial ABG.
Statistical analysis
Summary statistics including frequencies (n), means and standard deviations (SD) are provided for all continuous variables, as well as percentages (%) for categorical variables.
Results
One hundred and fifty-six patients were included in the study over 11 weeks between November 2013 and February 2014. Those patients who died either before a second ABG could be collected (n=2) or soon after the second ABG was collected and recorded (n=3) were withdrawn from data analysis in view of the potential for their ABGs to confound the general clinical picture of the overall cohort.
The remaining cohort (n=151) provided observations of 250 ABG measures with 52 single measures (52 patients who were extubated prior to repeat ABG) and 198 repeated measures. Patient characteristics are presented in Table  1 . The median age was 55 years and patients were mostly male (63%). Admission diagnostic groupings were diverse with mean APACHE II score of 19. The mean time that Primary findings of those patients successfully extubated before the second ABG (following six to 30 hours intubation) 1. Twenty-three (44%) patients were hyperoxic on their last ABG prior to extubation (Figure 1 ). 2. Forty-six (88%) were receiving FiO 2 between 0.3 and 0.4 ( Figure 1 ) and all of these patients had SaO 2 and SpO 2 of 97% or above. 3. Twelve (23%) patients were extubated successfully with low PaO 2 (receiving FiO 2 ranging from 0.3 to 0.5). 4. SpO 2 measures were higher than SaO 2 measures in the low PaO 2 groups (Figure 2 ). Data presented as *mean (range); ^mean (standard deviation); FiO 2 , inspired oxygen fraction; PaO 2 , arterial partial pressure of oxygen, mmHg; SpO 2 , pulse oximetry saturation of oxygen %; SaO 2 , arterial oxygen saturation %. 
Number of patients
Primary findings of those patients remaining intubated at the time of second ABG sampling
1. Oxygenation (Figure 3) : a. Approximately one-third of the cohort had normal PaO 2 on initial ABG sampling and this increased slightly to 37% by the second sampling. b. Over half the cohort (52%) were hyperoxic on initial ABG sampling and 40% were hyperoxic on repeat sampling. c. Four patients were severely hyperoxic (PaO 2 >202.5 mmHg) on initial ABG sampling (FiO 2 0.3; 0.45; 0.5; 0.8 respectively), and two were severely hyperoxic on repeat measurement (FiO 2 0.3 for both). d. The hypoxic group comprised the lowest number of patients, with 15% of the group hypoxic on initial ABG sampling and 22% hypoxic on repeat sampling.
Saturation of O 2 :
a. All hyperoxic patients had SaO 2 of 97%-100%, and almost all (94% and 95% of first and second observations respectively) had SpO 2 of 97%-100%. b. Lowest SpO 2 and SaO 2 measured were 90% and 88% respectively and both of these measurements were recorded at the time of the second observation. Both of these patients had their FiO 2 titrated from the first observation, one down and one up. c. SpO 2 measures were higher than SaO 2 measures in the low PaO 2 groups (Figure 2 ). 3. Titration of FiO 2 (Figure 4 ) from first to second ABG: a. Overall titration occurred in 31% of patients (10% FiO 2 up; 21% FiO 2 down). b. All three patients with severe hyperoxia and FiO 2 >0. 3 were titrated down to FiO 2 0.3 for the second observation. c. Twenty-six (26% of patients) had FiO 2 >0.4 in the first observation; this reduced to 21 (21% of patients) by the second observation.
Discussion
It is encouraging that the mean FiO 2 delivered across all observations was less than 0.4 such that the majority of our cohort received O 2 at a lower rate than that purported to create O 2 toxicity 9 . The mean PaO 2 reported here is some 14 mmHg higher than recent Australian ICU data 16 , however there were a similar proportion (less than half) of all observations in the hyperoxic range, and half the proportion of patients in the severely hyperoxic range (2% versus 4%). It is important to consider that consistent with other studies, our cohort demonstrated hyperoxia in patients receiving an FiO 2 of only 0.3 16 .
Although there are many examples in the literature where FiO 2 levels between 0.21 and 0.4 are grouped together as an "acceptably low FiO 2 " 10 , presumably based on normal atmosphere fraction and what is safe from a O 2 toxicity perspective, it is important to consider whether a room air FiO 2 of 0.21 is actually utilised in the majority of Australian ICUs. Recent data suggests it accounts for only a very small proportion (1%) of observations 16 . The lowest FiO 2 delivered to any patient during the current study was 0.3, and across all observations, it was delivered to approximately 40% of the population. Despite lack of departmental guidelines stating explicit parameters, it is apparent that there is a floor of O 2 prescription in our ICU that is higher than room air.
It is also worth considering that if hyperoxia is present despite an 'acceptable' FiO 2 , reactive O 2 intermediates are likely to form in the lung and potentially cause subclinical lung injury. It would thus still be advisable to titrate down FiO 2 whenever hyperoxia is present until 0.21 is attained. This practice however does not seem to be adopted in Australian ICUs and a target FiO 2 is used, rather than a more pathophysiological target PaO 2 . By continuing to seek small improvements in numerous parameters that influence outcome, the cumulative result may be improvement in survival and quality of recovery in ICU patients. While we recognise that hyperoxia is likely to have no detrimental effect in the uncomplicated patient group, there is a possibility that other outcomes (such as length of mechanical ventilation and length of ICU stay) may be influenced by the delivery of higher FiO 2 than that required. It may follow that reducing FiO 2 to that of room air in these patients may facilitate their earlier separation from MV and discharge from ICU and this may result in cost savings. Further studies are needed to explore this effect.
In terms of titration, our data suggests that within the 12 hours subsequent to the first ABG sample, there was titration of FiO 2 (either up or down) in just over one-third of the patients. If we remove the patients who were already at the floor of FiO 2 of 0.3, the proportion of those titrated rises to 45% of the cohort. In other words, a further 39 patients might have been titrated further had the lowest acceptable FiO 2 of 0.21 (room air) been recommended. There was therefore the potential for more hyperoxic patients-including the two that were very hyperoxic on an FiO 2 of 0.3-to have become oxygenated within normal limits. The lack of titration of patients receiving low end FiO 2 has been demonstrated previously in the literature, with up to 88% of hyperoxic patients on an FiO 2 of ≤0.4 receiving no adjustment 16 .
There were some discrepancies between the SaO 2 and the SpO 2 . This is not a new phenomenon and has been described in the literature previously 17 . Although it is not unexpected that SpO 2 may underestimate the SaO 2 (for example, with poor interface or with variable peripheral circulation on which oximetry relies), the reverse, whereby SaO 2 estimates were less than SpO 2 occurred in the hypoxic group. Explanation for this is less clear, but it may simply be that the timing of the observation and sampling were not simultaneous, or that the saturations of this subset of the population were more variable.
Finally, it is of interest to note that 52 patients (34% of the whole cohort) were successfully extubated before the second ABG, with 23 (44%) of these being hyperoxic. Although it is beyond the scope of this study to follow this cohort, presumably-as none died or were reintubated-there were no sequelae to exposure to hyperoxia in this group.
Strengths and limitations of the study
A strength of this study is that actual measurements were collected, such that the actual practice of oxygenation prescription rather than self-reported estimates 18 are provided. In addition, clinicians were unaware of the data collection during the collection period and this avoided any Hawthorne effect.
The main limitation of the study pertains to the retrospective data collection method and the relatively small number of patients from a single site which may limit the extent to which results may be generalised. However rates of FiO 2 applied and ABG PaO 2 results presented appear similar to that of other recent studies involving Australian tertiary ICUs 16 . 
Future study
It may be that further studies are needed to see if reducing FiO 2 to that of room air might facilitate normalisation of oxygenation and less hyperoxia. We would postulate further that normalisation of these parameters may even promote a faster wean from MV.
Conclusion
The majority of the cohort were observed to be receiving O 2 at a lower FiO 2 than that purported to create oxygen toxicity 9 . Morning gases were taken at a time suggested by ICU ward guidelines, and on review of these measures, almost one-third of the cohort had their first FiO 2 titrated (either up or down). There was a floor effect in that no patients were ventilated using an FiO 2 <0.3.
